Kiniksa Pharmaceuticals International, plc
78.52USD
+1.4300 (+1.85%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 220.2M | 270.3M | 423.2M | 677.6M | 993.7M | 1.2B |
| Q1 | 32.2M | 48.3M | 79.9M | 137.8M | 214.3M | — |
| Q2 | 27.0M | 71.5M | 108.6M | 156.8M | — | — |
| Q3 | 99.1M | 67.0M | 112.2M | 180.9M | 259.6M | — |
| Q4 | 61.9M* | 83.4M* | 122.5M* | 202.1M* | 276.1M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 2.60 | .200 | -.600 | .750 | 1.16 | 1.62 |
| Q1 | -.360 | -.180 | -.250 | .110 | .270 | — |
| Q2 | -.290 | .210 | -.060 | .230 | — | — |
| Q3 | 3.18 | -.200 | -.180 | .230 | .315 | — |
| Q4 | .063* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .351* |
| -.124* |
| .180* |
| .287 |
| — |